Philips shines light on value of acquisitions, big and small

Money

Royal Philips ($PHG) is doing alright for itself, per earnings discussed during a recent call. The company's Healthtech businesses saw sales grow at about 5%, driven by its Personal Health and Connected Care & Health Informatics groups.

This boost also comes in part thanks to the acquisitions Philips has made, specifically that for Volcano. Philips shelled out a cool $1.2 billion for the device maker back in late 2014. The aim was to earn some extra footing in catheter-based imaging and to boost offerings in its healthcare unit.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

According to President and CEO François van Houten, the investment was worth it.

“Philips Volcano is really performing well, demonstrating again this quarter both the benefits of the acquisition and the success of the integration,” he said during the call “In the second quarter, we delivered another strong quarter of double-digit comparable sales growth and continued operational improvements driven by growth across the smart catheter product portfolio, synergies with the Image-Guided Therapy Systems business and expansion into new geographies.”

Still, Volcano isn’t the only acquisition that seems to be worth Philips’ while, and van Houten has high hopes for other recent add-ons. PathXL joined the ranks of the Philips-acquired just last month, and van Houten noted the amount of potential he feels that deal brings on.

“With this complementary acquisition, we can build on our digital pathology solutions offering and leverage PathXL's capabilities in the fast-growing image analysis and tissue pathology software field,” he said during the call. “We will be an even more attractive partner for global medical institutions as they transition to digitize pathology workflows by solving needs in computational pathology education, workflow solutions and image analytics.”

PathXL also opens up some potential by way of health informatics. “The acquisition of PathXL is a nice example of a company that is very strong in image interpretation, thereby assisting the diagnosis of, for example, cancer patient,” van Houten explained.

The CEO also noted he is looking forward to opportunities in Population Health Management, specifically those coming from Philips’ acquisition of Wellcentive.  

“This is about analytics on the one hand and care coordination, supporting doctors, nurses both in the hospital enterprise but also with primary care and ambulances to collaborate together in the cloud,” van Houten explained during the call. “The acquisition last week of Wellcentive is a nice example to boost our analytics capabilities of data mining to enable Population Health Management.”

- here's the press release
- check out the earnings call transcript

Related Articles:
Philips acquires Wellcentive, boosts connected care offerings
Philips snaps up Northern Irish digital pathology startup PathXL
Philips shells out $1.2B for Volcano to gain ground in imaging therapy

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.